Mimotopes to produce peptides for Invitrogen
Thursday, 06 October, 2005
Mimotopes, a wholly owned subsidiary of PharmAust (ASX:PAA), is to supply California-based life science technology group Invitrogen Corporation (NASDAQ:IVGN) with custom pre-clinical peptides for Invitrogen's customers worldwide.
The preferred outsourcing agreement is on a 12-month rolling term. An initial standing order of custom peptides has been placed valued at between AUD$130,000 and AUD$200,000 per month. Mimotopes expects to generate initial revenues of over AUD$1.5 million per annum from the contract.
With a market capitalisation of US$4 billion, Invitrogen provides technologies for disease research, drug discovery and commercial bioproduction to research institutions, pharmaceuticals and biotechnology companies.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
